Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading Volume - Time to Buy?
Aquestive Therapeutics (NASDAQ:AQST) experienced a significant surge in trading volume, with shares rising 8.2% to $4.595. While analyst sentiment is generally positive with an average "Buy" rating and an $8.50 price target, the company recently missed earnings expectations despite exceeding revenue. Institutional ownership is at 32.45%, but a director recently sold 25,000 shares.
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan
Daniel Barber, President and CEO of Aquestive Therapeutics, Inc. (NASDAQ: AQST), sold 25,000 shares of the company's common stock on August 17, 2026, at a weighted average price of $4.2867 per share. This transaction was conducted under a pre-established Rule 10b5-1 plan, and following the sale, Barber beneficially holds 585,574 shares of common stock. The details were disclosed in a Form 4 filing with the SEC on August 19, 2026.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) for alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist with the investigation. The firm represents investors in class actions on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed
Aquestive Therapeutics' Chief Commercial Officer, Sherry Korczynski, had 2,714 shares of company common stock withheld to cover tax obligations stemming from the vesting of Restricted Stock Units. The shares were valued at $4.25 each. Following this transaction, Korczynski directly holds 235,689 shares of Aquestive Therapeutics common stock.
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan
Aquestive Therapeutics, Inc. (AQST) CEO Daniel Barber sold 25,000 shares of common stock on August 17, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $4.2867, ranging from $4.24 to $4.35 per share. Following this transaction, Mr. Barber directly holds 585,574 shares of the company's common stock.
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST
Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a broadly positive "Buy" rating with a consensus price target of $8.50.
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen
Aquestive Therapeutics (NASDAQ:AQST) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen analysts. The company reported a Q2 earnings per share miss of ($0.18) against an estimated ($0.10), although revenue of $13.82 million exceeded the $11.42 million consensus. Despite the downgrade, other analysts maintain a consensus "Buy" rating with an average price target of $8.50 for AQST.
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission
Aquestive Therapeutics (AQST) stock saw a 4% dip despite reporting improved Q2 2026 financials, with a narrowed net loss and US$98.5m in cash. The company is nearing resubmission of its Anaphylm New Drug Application to the FDA, having addressed all Complete Response Letter requests, aiming to pivot epinephrine treatment towards a needle-free oral film. However, concerns persist regarding ongoing adjusted EBITDA losses, cash burn, and the lack of an FDA acceptance letter or review clock for Anaphylm, which continue to fuel a bearish sentiment on the stock.
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
LifeSci Capital analyst Francois Brisebois has reaffirmed a Buy rating for Aquestive Therapeutics (AQST.US), maintaining a target price of $10. According to TipRanks data, Brisebois has a 43.0% success rate and a 6.3% average return over the past year. This report highlights the analyst's consistent positive outlook on the pharmaceutical company.
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST
Wasatch Advisors LP significantly increased its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 57.8% in Q2, bringing its total holding to 1.39 million shares valued at $5.76 million. Despite institutional investors collectively owning 32.45% of the company and a "Buy" consensus rating from analysts, Aquestive reported a wider-than-expected Q2 loss and issued full-year revenue guidance below consensus.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts
Aquestive Therapeutics (NASDAQ:AQST) has received an average "Buy" rating from analysts, with a consensus 12-month price target of $8.50. Despite exceeding second-quarter revenue expectations, the company reported a larger-than-expected loss per share and issued full-year revenue guidance below analyst consensus. Insider selling and institutional trading activity were also noted in the report.
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission
Aquestive Therapeutics (AQST) stock experienced a 4% dip despite positive Q2 results showing increased liquidity and reaffirmed revenue guidance. The company is nearing resubmission of its Anaphylm New Drug Application, with management addressing FDA concerns. However, ongoing adjusted EBITDA losses and the dependence on a single late-stage asset raise concerns about cash burn and financing risks for investors.
Aquestive Therapeutics Releases Q2 2026 Financial Results
Aquestive Therapeutics (AQST) reported a Q2 2026 diluted loss per share of $0.18, exceeding the expected loss of $0.11, with total revenue reaching $13.8 million, a 38.0% increase year-over-year. The company's net loss for the quarter was $22.9 million, and it ended with $98.5 million in cash and cash equivalents. Aquestive Therapeutics set its full-year revenue guidance between $46.0 million and $50.0 million.
Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AQST) 2026-08-12
Aquestive Therapeutics, Inc. (AQST) published its Q2 2026 earnings call presentation on August 12, 2026. The company reported an EPS of -$0.07, beating estimates by $0.05, and revenue of $13.82 million, a 38.15% year-over-year increase, beating estimates by $2.26 million. This presentation provides details discussed during their earnings call.
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026
Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in Q3 2026, supported by positive human factors and pharmacokinetic study results, and is preparing for a potential launch focusing on allergists. Aquestive maintained its full-year 2026 revenue guidance of $46 million to $50 million.
Aquestive Therapeutics Q2 Loss Widens, Revenue Rises
Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected to range from -$40 million to -$35 million.
Aquestive Therapeutics: Q2 Earnings Snapshot
This article provides a brief "Q2 Earnings Snapshot" for Aquestive Therapeutics. It is a very short piece, indicating that the company's Q2 earnings were reported.
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics announced its Q2 2026 financial results, highlighting progress with Anaphylm™ (dibutepinephrine) sublingual film, including successful completion of human factors and pharmacokinetic studies. The company remains on track to resubmit the Anaphylm NDA to the FDA in Q3 2026 and plans ex-U.S. filings. Total revenues increased to $13.8 million, up 38% year-over-year, while the net loss was $22.9 million, partly due to a one-time debt extinguishment loss.
Aquestive Plans to Take Epi Film Back to FDA with Positive Data
Aquestive Therapeutics plans to resubmit its drug application for Anaphylm, an oral dissolving film for severe allergic reactions, to the FDA this fall. This follows the completion of two additional studies requested by the FDA, which have yielded positive results regarding revised packaging, ease of use, and epinephrine absorption. The company is confident in its new data and aims for expedited review, with plans to seek approval in Canada, Europe, and the UK in late 2026.
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7.1% - Here's Why
Aquestive Therapeutics (NASDAQ:AQST) saw its shares rise 7.1% to $4.595, with a market capitalization of approximately $574 million. The company's stock holds a consensus "Buy" rating from analysts with an average price target of $8.50, driven by its recent beat on quarterly earnings expectations. Despite positive analyst sentiment and strong earnings, company insiders have recently sold shares under pre-arranged trading plans.
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ sublingual film, an epinephrine product for severe allergic reactions. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in the third quarter of 2026, addressing previous concerns regarding packaging and administration. The studies demonstrated significant improvements in ease of use and effective drug delivery, even with some incorrect placements.
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics (AQST) announced positive results from human factors and pharmacokinetic validation studies for its Anaphylm sublingual film, a severe allergy treatment. These studies address prior FDA feedback, demonstrating significant improvements in product usability and effective drug delivery even with slight misplacement. The company plans to resubmit its New Drug Application to the FDA in Q3 2026 and is pursuing regulatory approvals in other regions.
Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside
Aquestive Therapeutics Inc (AQST) is preparing to release its Q2 2026 earnings on August 11, 2026, with revenue expected at $11.42 million and earnings at $-0.12 per share. While analysts predict a significant upside of 125.61% based on average price targets, GuruFocus's GF Value suggests a 34.52% downside from the current price of $3.94. The company beat both revenue and earnings expectations in the previous quarter, leading to a 14.53% stock increase.
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film
Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. The company believes Anaphylm has the potential to be the first non-invasive, orally delivered epinephrine product for severe allergic reactions.
Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials
Aquestive Therapeutics has released supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program. A resubmission human factors study showed fewer use issues compared to the original NDA study, with a median open time reduced to 3 seconds. A pharmacokinetic study indicated self-administration was comparable to clinician administration, despite lower exposure with purposeful top-of-tongue misplacement, which still produced a clinically meaningful pharmacodynamic response.
Aquestive Reports Positive Human Factors and PK Results for Anaphylm, Plans NDA Resubmission Q3 2026
Aquestive announced positive human factors and pharmacokinetic (PK) results for Anaphylm, indicating significant improvements in usability and comparable drug delivery. These results support the planned New Drug Application (NDA) resubmission in Q3 2026 for the epinephrine treatment. The study showed reduced errors in self-administration and clinically meaningful pharmacological responses, even with misplaced application.
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aquestive Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and its officers. The lawsuit, filed on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026, alleges that the company made false and misleading statements regarding the approval and launch timeline of its drug Anaphylm, which faced significant human factors risks. Investors who suffered losses have until May 4, 2026, to request to be appointed as lead plaintiff.
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results are intended to support the planned resubmission of the company's New Drug Application (NDA) to the FDA in the third quarter of 2026 for the treatment of severe allergic reactions. The studies showed significant improvements in packaging usability and clinically meaningful pharmacodynamic results, even with incorrect film placement.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) who bought securities prior to June 16, 2025, and still hold them. The investigation aims to determine if Aquestive officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information, emphasizing that they operate on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (NASDAQ:AQST) securities. The investigation focuses on whether Aquestive officers and/or directors engaged in corporate wrongdoing, particularly for investors who purchased shares before June 16, 2025, and still hold them. The firm encourages affected investors to contact them for more information and to assist with the investigation.
Earnings Preview: AQST to Report Financial Results Post-market on August 11
AQST is scheduled to announce its financial results after the market closes on August 11. Investors will be closely watching the earnings report for insights into the company's performance and future outlook. This preview serves as a heads-up for those tracking AQST's financial news.
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain officers. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for its drug Anaphylm, specifically related to human factors and regulatory risks. Shareholders who purchased securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit by May 4, 2026, to seek damages.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (NASDAQ:AQST) for potential corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, meaning investors incur no direct cost unless the firm is successful in recovering funds.
AQST|Aquestive Therapeutics Inc|Price:3.725|Chg%:+0.125
This article provides a comprehensive stock analysis of Aquestive Therapeutics Inc (AQST) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has healthy fundamentals, high growth potential, and its valuation is considered fairly valued. Despite recent weak market performance, analysts have rated it as a Buy with a significant upside potential.
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) securities who bought shares before June 16, 2025, and still hold them. The investigation concerns whether Aquestive and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist with the investigation, with no cost to the investors.
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these results and recent developments. Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, including its proprietary PharmFilm® and AdrenaVerse™ platforms.
Aquestive Therapeutics Inc (AQST) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aquestive Therapeutics Inc (AQST), highlighting its current price momentum score, support and resistance levels, and indicator readings. It details various technical indicators like MACD, RSI, and moving averages, offering "Sell", "Neutral", and "Buy" signals. The analysis suggests a Neutral signal based on current indicators and addresses frequently asked questions regarding technical ratings and moving averages.
Aquestive Therapeutics to Report Second Quarter 2026
Aquestive Therapeutics will report its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will also host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these results and recent developments. Aquestive Therapeutics is a pharmaceutical company focused on innovative science and delivery technologies, including its proprietary PharmFilm® and AdrenaVerse™ platforms.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Aquestive securities before June 16, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aquestive Therapeutics Inc (AQST) Institutional Confidence
Aquestive Therapeutics Inc (AQST) has an institutional shareholding score of 5.00, placing it 72nd within the Pharmaceuticals industry. Institutional investors collectively hold 60.30% of the shares, marking a 16.75% increase quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding 912.50K shares.
Aquestive Therapeutics Inc (AQST) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Aquestive Therapeutics Inc (AQST) focusing on its dividend and stock split history. It notes that the company has not distributed any dividends in the past five years. The page also presents current stock performance data, including market cap and recent price changes.
Aquestive Therapeutics Inc (AQST) Income Statement
This article provides a detailed quarterly and annual income statement for Aquestive Therapeutics Inc (AQST), allowing investors to analyze the company's financial performance and operational efficiency. It presents data spanning several fiscal years, covering metrics such as total revenue, operating expenses, net income, and basic/diluted earnings per share. The piece also includes a FAQ section to help users understand how to interpret the income statement and identify key financial indicators for AQST.
ETFs Investing in Aquestive Therapeutics, Inc. Stocks
This article lists various ETFs that include Aquestive Therapeutics, Inc. (AQST) stocks in their holdings. It provides detailed financial data for each ETF, such as market value, weight of AQST in the fund, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies, including passive and active management, and focus on sectors like health care, small-cap, micro-cap, and biotechnology.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aquestive Therapeutics, Inc. (NASDAQ:AQST) regarding potential corporate wrongdoing by its officers and/or directors. The firm is encouraging shareholders who purchased Aquestive securities prior to June 16, 2025, and continue to hold them, to contact them to assist in the investigation. The representation of investors in class actions is on a contingency fee basis.
Aquestive Therapeutics president and CEO Daniel Barber sells $100,191 in stock
Aquestive Therapeutics President and CEO Daniel Barber sold a total of $100,191 worth of company stock through two transactions on July 15 and July 16, 2026. These sales reduced his direct ownership to 610,574 shares. The sales occurred while the stock was trading at $4.05, down 39% year-to-date, and InvestingPro analysis suggests the stock is overvalued and the company is not profitable over the last twelve months.
Enterprise value to EBITDA forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST
This page provides information on the enterprise value to EBITDA forward for Aquestive Therapeutics, Inc. (NASDAQ:AQST). It is part of a larger financial data and market analysis platform, offering various tools and community features for investors. The content specifically highlights the financial metric for AQST.
Price to book forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST
This page provides financial information for Aquestive Therapeutics, Inc. (NASDAQ: AQST), specifically focusing on its forward price-to-book ratio. It appears to be a stub or data-only page from TradingView, offering an overview of the company's financials without detailed analysis in this snapshot.
Enterprise value to revenue forward of Aquestive Therapeutics, Inc. – NASDAQ:AQST
This article focuses on the enterprise value to revenue forward metric for Aquestive Therapeutics, Inc. (NASDAQ: AQST). It presents this financial data within the context of the company's profile on TradingView, a financial markets platform. The content is primarily a data point with minimal descriptive text.
Aquestive Therapeutics (AQST) CEO Barber sells 25,000 shares between $4.00 and $4.04
Aquestive Therapeutics (AQST) CEO Daniel Barber sold a total of 25,000 common shares on July 15-16, 2026, at prices ranging from $4.00 to $4.04 per share. These transactions were executed under a Rule 10b5-1 trading plan. Following the sales, Barber directly holds 610,574 shares of the company.
Insider Sell: Aquestive Therapeutics Inc (AQST) President and CE
Aquestive Therapeutics Inc (AQST) President and CEO Daniel Barber sold 25,000 shares of the company on July 16, 2026, reducing his total holdings to 610,574 shares. This transaction follows a pattern of 19 insider sells and no buys over the past year. With the stock trading at $4.01 and a GF Value of $2.11, the company appears significantly overvalued according to GuruFocus's intrinsic value estimate.
